Skip to main navigation
  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share
logo
  • About Omeros
    • About Omeros
    • Leadership
  • Science
    • Research Areas
    • Discovery Technologies
    • Scientific
      Publications
  • Pipeline
    • Pipeline Overview
    • OMIDRIA®
    • Narsoplimab
      (OMS721)
    • OMS824
    • OMS405
    • OMS527
    • OMS906
    • MASP-2, MASP-3,
      MASP-2/3
    • GPR174
    • GPR161
  • Patients
    • Commitment
      to Patients
  • Search
  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share

Investor Relations

  • Press Releases
  • Events
    • Upcoming Events
    • Archived Events
  • Governance
    • Highlights
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Quarterly Results
    • Annual Reports
    • Proxy Statements
    • SEC Filings
    • Analyst Coverage
    • Presentations & Documents
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Historical Prices
    • Investment Calculator
  • FAQs
  • Contact Us

Annual Reports

Financial Information

  • Quarterly Results
  • Annual Reports
  • Proxy Statements
  • SEC Filings
  • Analyst Coverage
  • Presentations & Documents

Annual Reports

2023 Annual Report 1.1 MB
2022 Annual Report 2 MB
2021 Annual Report 2.6 MB
2020 Annual Report 2.5 MB
2019 Annual Report 1.4 MB
2017 Annual Report 1 MB
2016 Annual Report 1 MB
2015 Annual Report 11.8 MB
2014 Annual Report 3.5 MB
2013 Annual Report 1.8 MB
2012 Annual Report 2.6 MB
2011 Annual Report 1.2 MB
2010 Annual Report 724.9 KB
2009 Annual Report 2.3 MB

Omeros logo©2025 Omeros Corporation, All rights reserved.

  • Site Map
  • Contact Us
  • Privacy Policy
  • Legal

  • Investors & News
    • Investors Overview
    • Press Releases
    • Events
    • Governance
    • Financial Information
    • Stock Information
    • FAQs
    • Contact Us
  • Careers
  • Contact Us
  • Share
  • About Omeros
    • About Omeros
    • Leadership
  • Science
    • Research Areas
    • Discovery Technologies
    • Scientific
      Publications
  • Pipeline
    • Pipeline Overview
    • OMIDRIA®
    • Narsoplimab
      (OMS721)
    • OMS824
    • OMS405
    • OMS527
    • OMS906
    • MASP-2, MASP-3,
      MASP-2/3
    • GPR174
    • GPR161
  • Patients
    • Commitment
      to Patients

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our Privacy Policy.
Agree

You are now leaving Omeros.com

Omeros makes no representation as to the accuracy of the information on sites we do not own or control and does not recommend or endorse content on any third-party websites. Your use of a third-party website is at your own risk and subject to the terms and conditions of that site.

Continue

© 2025 Omeros All rights reserved